產(chǎn)品描述: | Triciribine is a DNA synthesis inhibitor, also inhibits Akt and HIV-1/2 with IC50 of 130 nM, and 0.02-0.46 μM, respectively. |
靶點: |
HIV-1;HIV-2;DNA synthesis;HIV-1:0.02-0.46 μM (IC50);HIV-2:0.02-0.46 μM (IC50);Akt;HIVProtease;DNA/RNASynthesis |
體內(nèi)研究: |
Triciribine (TCBN) treatment, administered for 7 days after 14 days of hypoxia until 21 days of hypoxia is reached, reversed the vascular thickening as shown by immunohistochemistry and Western analyses. On the other hand, Rapamycin treatment did not prevent hypoxia-induced pulmonary alveolar haemorrhage and congestion. Triciribine partially inhibits progressive pruning of the vasculature |
參考文獻: |
1. Dieterle A, et al. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer. 2009 Aug 15;125(4):932-41. 2. Gürsel DB, et al. Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma. Neuro Oncol. 2011 Jun;13(6):610-21 3. Kucera LS, et al. Activity of triciribine and triciribine-5'-monophosphate against human immunodeficiency virus types 1 and 2. AIDS Res Hum Retroviruses. 1993 Apr;9(4):307-14. 4. Abdalla M, et al. The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis. Br J Pharmacol. 2015 Aug;172(16):4173-88. |
溶解性: |
DMSO : 100 mg/mL (312.21 mM; Need ultrasonic) |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
3.122 ml |
15.61 ml |
31.221 ml |
5 mM |
0.624 ml |
3.122 ml |
6.244 ml |
10 mM |
0.312 ml |
1.561 ml |
3.122 ml |
50 mM |
0.062 ml |
0.312 ml |
0.624 ml |
|
注意: |
部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。 |